SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc.,
an emerging biopharmaceutical company, today announced preclinical test
results demonstrating the utility of their lead drug candidate rC3-1 for
the treatment of the rare chronic blood disorder paroxysmal nocturnal
hemoglobinuria (PNH). The complete results will be presented at the XXII
International Complement Workshop in Basel, Switzerland, September 28,
2008.
The only treatment currently available for PNH patients is an anti-C5
antibody Soliris(TM) (eculizumab) sold by Alexion Pharmaceuticals, Inc.
rC3-1 promotes the enzymatic partial depletion of C3, the hub of the
complement cascade. Complement protein C3 is the master regulator of
complement protein C5 that mediates cell damage in PNH patients. The
reduction of C3 has been shown to reduce PNH cell destruction.
PNH is a rare debilitating and life-threading disease. PNH is an
acquired genetic blood disorder in which patients' red blood cells are
destroyed by complement, a component of the body's immune system. PNH
patients have a sub-population of red blood cells (PNH cells) that are
susceptible to immune complement-mediated destruction. In this study, PNH
cells from patients remained intact in blood serum treated with rC3-1 when
compared to non-treated serums.
"rC3-1 appears to be a promising new treatment alternative with several
benefits over the existing treatment," Commented Bill St. John CEO of
InCode. "The unique action of rC3-1, offers patients the potential for more
convenient self-administered dosing and physicians' a more cost effective
and flexible treatment option."
InCode is planning PNH clinical trials testing rC3-1. These trials will
provide a foundation for series of subsequent clinical trials addressing
macular degeneration, asthma and other autoimmune and inflammatory disease
indications.
InCode BioParmaceutics, Inc. is an emerging biotechnology company that
is developing a new class of recombinant proteins for the controlled
depletion of complement protein C3. The therapeutic potential for C3
depletion has been demonstrated in Macular Degeneration, Asthma, Rheumatoid
Arthritis, and autoimmune and inflammatory diseases. C3 depletion has also
been demonstrated as a useful adjuvant to surgery, transplantation and
cancer therapy. InCode is pursuing a progressive clinical development plan
focused on proof of concept trials.
See Also:
- BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
- FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
- Brain and Spinal Injuries in Georgia: A Needs Assessment and State Action Plan
- Transcept Pharmaceuticals to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference
- Concept of 'Raising the Bottom' Explored in Award-Winning Alcohol & Drug Addiction Book.
[Via Healthcare]
0 коментарі:
Post a Comment